PT  - JOURNAL ARTICLE
AU  - ALESSANDRO FEDERICO
AU  - VALERIA CONTI
AU  - GIUSY RUSSOMANNO
AU  - MARCELLO DALLIO
AU  - MARIO MASARONE
AU  - PAOLA STIUSO
AU  - CONCETTA TUCCILLO
AU  - MICHELE CARAGLIA
AU  - VALENTINA MANZO
AU  - MARCELLO PERSICO
AU  - AMELIA FILIPPELLI
AU  - CARMELINA LOGUERCIO
TI  - A Long-term Treatment with Silybin in Patients with Non-alcoholic Steatohepatitis Stimulates Catalase Activity in Human Endothelial Cells
DP  - 2017 Jul 01
TA  - In Vivo
PG  - 609--618
VI  - 31
IP  - 4
4099  - http://iv.iiarjournals.org/content/31/4/609.short
4100  - http://iv.iiarjournals.org/content/31/4/609.full
SO  - In Vivo2017 Jul 01; 31
AB  - Aim: To compare levels of oxidative stress markers in patients' sera with non-alcoholic steatohepatitis (NASH) treated for 12 months (T12) with silybin conjugated with phosphatidylcholine (Realsil®) (R) or placebo (P) and investigate oxidative stress responses in human endothelial cells conditioned with patients' sera. Patients and Methods: We recruited twenty-seven patients with histological NASH. We measured thiobarbituric acid reactive substances (TBARS), superoxide dismutase (SOD) and catalase (CAT) activities in human endothelial cells conditioned with patients' sera exposed or not to H2O2. Results: We found in decreased-TBARS patients' sera, at T12, a decrease of alanine aminotransferase (p=0.038), transforming growth factor-beta (p=0.009) and procollagen I (p=0.001). By dividing patients into two groups, increased (P-I/R-I) and decreased TBARS (P-II/R-II) at T12 compared to T0, we found an increased CAT activity in conditioned endothelial cells at T12 in both groups (p=0.05 and p=0.001, respectively). Conclusion: Realsil® may be effective against endothelial dysfunction by stimulating the cellular antioxidant defense.